Abstract
The pH-centered treatment for cancer needs powerful help from anti-angiogenic schemes. The administration of low, uninterrupted doses of a chemotherapeutic drug associated with a non-steroidal anti-inflammatory compound, usually a selective COX2 inhibitor, has an antiangiogenic effect that usually achieves a stable disease, lasting approximately for 1 year. For reasons not fully clarified, resistance generally develops after a year and there is often an increase in metastasis. When pH reversion treatments are used in association with metronomic anti-angiogenesis there is a higher rate of response with synergistic effects against the tumor and a prolonged delay of resistance. The rate of metastasis, which seems to increase with metronomic antiangiogenesis as a stand-alone treatment was not found when it was associated with the pH reversal approach.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: An Innovative Approach to Understanding and Treating Cancer: Targeting pH
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
